Cefepime + VNRX-5133

Unassigned

New Medicines

Complicated urinary tract infection

Information

New formulation
VenatoRx
VenatoRx

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

VNRX-5133 is a beta-lactamase inhibitor
US CDC estimates that antibiotic-resistant infections affect at least two million people in the United States alone [1].
Complicated urinary tract infection
Intravenous